Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease.

Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, Ashford E, Retout S, Hofmann C, Delmar P, Klein G, Andjelkovic M, Dubois B, Boada M, Blennow K, Santarelli L, Fontoura P; SCarlet RoAD Investigators.

Alzheimers Res Ther. 2017 Dec 8;9(1):95. doi: 10.1186/s13195-017-0318-y.

2.

PET/MR Imaging: New Frontier in Alzheimer's Disease and Other Dementias.

Zhang XY, Yang ZL, Lu GM, Yang GF, Zhang LJ.

Front Mol Neurosci. 2017 Nov 1;10:343. doi: 10.3389/fnmol.2017.00343. eCollection 2017. Review.

3.

Partial volume correction for PET quantification and its impact on brain network in Alzheimer's disease.

Yang J, Hu C, Guo N, Dutta J, Vaina LM, Johnson KA, Sepulcre J, Fakhri GE, Li Q.

Sci Rep. 2017 Oct 12;7(1):13035. doi: 10.1038/s41598-017-13339-7.

4.

Correlation between two methods of florbetapir PET quantitative analysis.

Breault C, Piper J, Joshi AD, Pirozzi SD, Nelson AS, Lu M, Pontecorvo MJ, Mintun MA, Devous MD.

Am J Nucl Med Mol Imaging. 2017 Jul 15;7(3):84-91. eCollection 2017.

5.

18F-Florbetaben PET beta-amyloid binding expressed in Centiloids.

Rowe CC, Doré V, Jones G, Baxendale D, Mulligan RS, Bullich S, Stephens AW, De Santi S, Masters CL, Dinkelborg L, Villemagne VL.

Eur J Nucl Med Mol Imaging. 2017 Nov;44(12):2053-2059. doi: 10.1007/s00259-017-3749-6. Epub 2017 Jun 22.

6.

Optimized classification of 18F-Florbetaben PET scans as positive and negative using an SUVR quantitative approach and comparison to visual assessment.

Bullich S, Seibyl J, Catafau AM, Jovalekic A, Koglin N, Barthel H, Sabri O, De Santi S.

Neuroimage Clin. 2017 May 13;15:325-332. doi: 10.1016/j.nicl.2017.04.025. eCollection 2017.

7.

Communicating mild cognitive impairment diagnoses with and without amyloid imaging.

Grill JD, Apostolova LG, Bullain S, Burns JM, Cox CG, Dick M, Hartley D, Kawas C, Kremen S, Lingler J, Lopez OL, Mapstone M, Pierce A, Rabinovici G, Roberts JS, Sajjadi SA, Teng E, Karlawish J.

Alzheimers Res Ther. 2017 May 4;9(1):35. doi: 10.1186/s13195-017-0261-y. Review.

8.

Recent Progress in Alzheimer's Disease Research, Part 3: Diagnosis and Treatment.

Hane FT, Robinson M, Lee BY, Bai O, Leonenko Z, Albert MS.

J Alzheimers Dis. 2017;57(3):645-665. doi: 10.3233/JAD-160907. Review.

9.

Classification of amyloid status using machine learning with histograms of oriented 3D gradients.

Cattell L, Platsch G, Pfeiffer R, Declerck J, Schnabel JA, Hutton C; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage Clin. 2016 May 10;12:990-1003. eCollection 2016.

10.

Fluselenamyl: A Novel Benzoselenazole Derivative for PET Detection of Amyloid Plaques (Aβ) in Alzheimer's Disease.

Sundaram GS, Dhavale DD, Prior JL, Yan P, Cirrito J, Rath NP, Laforest R, Cairns NJ, Lee JM, Kotzbauer PT, Sharma V.

Sci Rep. 2016 Nov 2;6:35636. doi: 10.1038/srep35636.

11.

Quantitative multimodal multiparametric imaging in Alzheimer's disease.

Zhao Q, Chen X, Zhou Y.

Brain Inform. 2016 Mar;3(1):29-37. Epub 2016 Jan 8.

12.

Biomarkers for the Early Detection and Progression of Alzheimer's Disease.

Counts SE, Ikonomovic MD, Mercado N, Vega IE, Mufson EJ.

Neurotherapeutics. 2017 Jan;14(1):35-53. doi: 10.1007/s13311-016-0481-z. Review.

PMID:
27738903
13.

Phantom criteria for qualification of brain FDG and amyloid PET across different cameras.

Ikari Y, Akamatsu G, Nishio T, Ishii K, Ito K, Iwatsubo T, Senda M.

EJNMMI Phys. 2016 Dec;3(1):23. Epub 2016 Oct 6.

14.

Untangling tau imaging.

Villemagne VL, Okamura N, Rowe CC.

Alzheimers Dement (Amst). 2016 Jun 4;4:39-42. doi: 10.1016/j.dadm.2016.05.001. eCollection 2016. Review.

15.

A systematic review and meta-analysis of (18)F-labeled amyloid imaging in Alzheimer's disease.

Yeo JM, Waddell B, Khan Z, Pal S.

Alzheimers Dement (Amst). 2015 Mar 29;1(1):5-13. doi: 10.1016/j.dadm.2014.11.004. eCollection 2015 Mar.

16.

Candidate PET Radioligand Development for Neurofibrillary Tangles: Two Distinct Radioligand Binding Sites Identified in Postmortem Alzheimer's Disease Brain.

Cai L, Qu B, Hurtle BT, Dadiboyena S, Diaz-Arrastia R, Pike VW.

ACS Chem Neurosci. 2016 Jul 20;7(7):897-911. doi: 10.1021/acschemneuro.6b00051. Epub 2016 May 19.

17.

Drug Development in Alzheimer's Disease: The Contribution of PET and SPECT.

Declercq LD, Vandenberghe R, Van Laere K, Verbruggen A, Bormans G.

Front Pharmacol. 2016 Mar 31;7:88. doi: 10.3389/fphar.2016.00088. eCollection 2016. Review.

18.

Insight into the Molecular Imaging of Alzheimer's Disease.

Arora A, Bhagat N.

Int J Biomed Imaging. 2016;2016:7462014. doi: 10.1155/2016/7462014. Epub 2016 Jan 10. Review.

19.

Role of Hybrid Brain Imaging in Neuropsychiatric Disorders.

Burhan AM, Marlatt NM, Palaniyappan L, Anazodo UC, Prato FS.

Diagnostics (Basel). 2015 Dec 4;5(4):577-614. doi: 10.3390/diagnostics5040577. Review.

20.

Reference tissue normalization in longitudinal (18)F-florbetapir positron emission tomography of late mild cognitive impairment.

Shokouhi S, Mckay JW, Baker SL, Kang H, Brill AB, Gwirtsman HE, Riddle WR, Claassen DO, Rogers BP; Alzheimer’s Disease Neuroimaging Initiative.

Alzheimers Res Ther. 2016 Jan 15;8:2. doi: 10.1186/s13195-016-0172-3.

Supplemental Content

Support Center